Seventy percent of elderly patients with acute myeloid leukemia (AML) who were treated with a combination of drugs aimed to make chemotherapy treatments effective and less toxic achieved remission or a slowing of disease progression, in a clinical study led by UPCI’s Annie Im, MD, an assistant professor of medicine in Pitt’s Division of Hematology/Oncology. The research is important because most elderly patients diagnosed with AML can’t tolerate the aggressive chemotherapy needed and tend to have more aggressive disease than younger patients, making prognosis poor.
To learn more, watch Dr. Im discuss the trial.
